Takeda Pharmaceuticals
Better Health, Brighter Future

Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Gastroenterology (GI), Rare Diseases and Neuroscience. We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines. We are focusing on developing highly innovative medicines that contribute to making a difference in people’s lives by advancing the frontier of new treatment options and leveraging our enhanced collaborative R&D engine and capabilities to create a robust, modality-diverse pipeline.

The Global Oncology Business Unit’s mission is not a quick or simple one, but we are up to the task: We aspire to cure cancer. Takeda’s legacy in oncology extends more than 25 years and includes a range of paradigm-changing therapies for hematologic cancers and solid tumors. Our therapies span treatments for multiple types of cancer, particularly those that have not traditionally been the focus of oncology R&D. The Global Oncology Business Unit markets several products in the U.S. and internationally.

For more than 70 years, Takeda has supplied vaccines to protect the health of people in Japan. Today, Takeda’s global vaccine business is applying innovation to tackle some of the world’s most challenging infectious diseases, such as dengue, Zika and norovirus. Our team brings an outstanding track record and a wealth of knowledge in vaccine development, manufacturing and global access to advance a pipeline of vaccines that address some of the world’s most pressing public health needs.